Trial Profile

A Phase 1, Open-Label, Multicenter, Dose Escalation Study of PRT1419 Injection as Monotherapy or in Combination With Azacitidine or Venetoclax in Patients With Relapsed/Refractory Myeloid or B-cell Malignancies

Status: Discontinued

Phase of Trial: Phase I

Latest Information Update: 05 Feb 2024

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Azacitidine (Primary) ; Azacitidine (Primary) ; PRT 1419 (Primary) ; Venetoclax (Primary)
Indications Acute myeloid leukaemia; Chronic lymphocytic leukaemia; Chronic myelomonocytic leukaemia; Haematological malignancies; Myelodysplastic syndromes; Myeloproliferative disorders; Non-Hodgkin's lymphoma
Focus Adverse reactions
Sponsors Prelude Therapeutics

29 Jan 2024 Status changed from active, no longer recruiting to discontinued.
16 Nov 2023 Status changed from recruiting to active, no longer recruiting.
03 Aug 2023 According to a Prelude Therapeutics media release, the Company will provide a clinical update on PRT1419 by year end.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com